<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04512872</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P41 1.1</org_study_id>
    <nct_id>NCT04512872</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects</brief_title>
  <official_title>A Pilot Phase 1, Double-Blind, Randomized, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Pilot Phase 1, Double-Blind, Randomized, Two-arm, Parallel group, Single-dose&#xD;
      Study to Evaluate the Safety and Pharmacokinetics of CT-P41 and EU-approved Prolia in Healthy&#xD;
      Male Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a pilot phase 1, randomized, double-blind, two-arm, parallel group, single-dose&#xD;
      study, which is designed to evaluate the safety, immunogenicity, PK and PD of CT-P41 and&#xD;
      EU-approved Prolia in healthy male subjects. Approximately 30 male subjects will be enrolled&#xD;
      and randomly assigned to one of the two treatment arms in a 1:1 ratio. In each treatment&#xD;
      group, all subjects will receive a single 60 mg dose of either CT P41 or EU-approved Prolia&#xD;
      by subcutaneous injection via a PFS on Day 1, followed by 134 days of safety, immunogenicity,&#xD;
      PK, and PD measurements.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Actual">May 4, 2021</completion_date>
  <primary_completion_date type="Actual">May 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate safety</measure>
    <time_frame>through study completion, up to day 134</time_frame>
    <description>safety in terms of treatment-emergent adverse events (TEAEs) of CT-P41 compared to that of EU-approved Prolia</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>CT-P41</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg/mL single dose administration, Solution for injection in PFS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU-approved Prolia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 mg/mL single dose administration, Solution for injection in PFS</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P41</intervention_name>
    <description>60 mg/mL single dose, Solution for injection in PFS</description>
    <arm_group_label>CT-P41</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU-approved Prolia</intervention_name>
    <description>60 mg/mL single dose, Solution for injection in PFS</description>
    <arm_group_label>EU-approved Prolia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects, between the ages of 28 and 55 years.&#xD;
&#xD;
          -  Subject with a BMI between 18.5 and 29.9 kg/m2.&#xD;
&#xD;
          -  Subject with albumin-adjusted total serum calcium ≥8.5 mg/dL (≥2.125 mol/L) and serum&#xD;
             25-OH vitamin D ≥20 ng/ml.&#xD;
&#xD;
          -  Male subject and their female partner of childbearing potential must agree to use a&#xD;
             highly effective method of contraception throughout the study and for 5 months after&#xD;
             the study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with a hypersensitivity to any component of denosumab.&#xD;
&#xD;
          -  Subject has a history of and/or current known risk factors for hypocalcemia and&#xD;
             osteonecrosis of jaw, and any clinically significant illness at investigator's&#xD;
             discretion.&#xD;
&#xD;
          -  Subject has a history of and/or concurrent use of medications such as an&#xD;
             investigational drug, monoclonal antibody, fusion protein, and biologics.&#xD;
&#xD;
          -  Subject has a history of and/or concurrent use of any therapy that might significantly&#xD;
             affect bone metabolism.&#xD;
&#xD;
          -  Subject is vulnerable.&#xD;
&#xD;
          -  Subject is not likely to complete the study for whatever reason in the opinion of the&#xD;
             Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Q-Pharm Pty Ltd</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

